Day: June 19, 2025

Official Title: Beamion BCGC-1: A Phase Ib Dose Escalation and Phase II Dose Optimization, Randomized, Open-Label, Multicenter Trial of Oral Zongertinib (BI 1810631) in Combination with Intravenous Trastuzumab Deruxtecan (T-DXd) or in Combination with Intravenous Trastuzumab Emtansine (T-DM1) for Treatment of Patients with Advanced HER2+ Metastatic Breast Cancer (mBC) and Metastatic Gastric …